Clinical Validation Momentum Recent CGUARDIANS II data demonstrating strong acute device outcomes and the potential for FDA approval of CGuard Prime TCAR creates a compelling selling narrative to high-volume vascular and neurointerventional centers seeking stroke prevention options.

TCAR Platform Expansion The introduction of the CGuard Prime TCAR implant and the CGUARDIANS III pivotal study with SwitchGuard neuro protection creates multiple sales opportunities across TCAR programs, including pilot deployments, training, and center-wide adoption in major health systems.

Mesh Differentiation CGuard Prime's outside MicroNet mesh design offers unique neurovascular protection by reducing plaque prolapse, backed by extensive clinical experience, which can be leveraged to differentiate sales pitches to surgeons and payers.

US Commercial Readiness Inducement equity grants to new employees and a Nasdaq listing signal ongoing expansion of InspireMD's commercial and clinical support capabilities in the United States, enabling scalable outreach to hospitals, surgeons, and procurement teams.

Market Engagement Active participation in investor conferences and ongoing data announcements provide pathways to accelerate relationships with key hospital accounts, KOLs, and distributors, and to build site-specific adoption programs and revenue growth.